Journal articleClin Cancer Res2021
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
- Journal
- Clin Cancer Res
- Published
- 10 June 2021
- Citations
- 165
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 4
- Cancer Therapeutics Program P30CA016520↗
- Immunobiology and immunotherapy of pancreatic cancer R01CA169123↗
- Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer R01CA229803↗
- Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗